Business
Alnylam Launches “Alnylam P⁵x25” Strategy for Planned Transition to a Top Five Biotech in Market Capitalization Over Next Five Years
– New 5-Year Strategy Represents Alnylam’s Commitment to Delivering Transformative Rare and Prevalent Disease Medicines for Patients Around the World Through
About this update from Alnylam Pharmaceuticals, Inc.
[{"type":"text","content":"\n– New 5-Year Strategy Represents Alnylam’s Commitment to Delivering Transformative Rare and Prevalent Disease Medicines for Patients Around the World Through Sustainable Innovation and Exceptional Financial Performance Driving Profitability –\n\n– In Addition, Company Announces Full Year 2020 Preliminary* Global Net Product Revenues for ONPATTRO® and GIVLAARI® of Approximately $306 Million and $55 Million, Respectively, and Strong Initial U.S. Demand for OXLUMOTM –\n\n CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nAlnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced its new 5-year strategy “Alnylam P5x25” focused on the Company’s planned transition to a top-5 biotech (measured by market capitalization) in the next 5 years through: sustainable innovation yielding transformative medicines for rare and common diseases for patients around the world and delivery of exceptional financial performance. Alnylam P5x25 extends the Company’s decade-long heritage of providing longer term, 5-year business strategy guidance, the most recent of which was known as Alnylam 2020. In addition, Alnylam today reported preliminary fourth quarter and full year 2020 global net product revenues for ONPATTRO and GIVLAARI and provided additional updates on the Company’s commercial launches, including initial OXLUMO demand.\n\nNew 5-Year Strategy: P5x25\nAlnylam ended last year exceeding all metrics for its Alnylam 2020 strategy, with 4 marketed products (versus 3), 12 clinical programs (versus 10), 6 of which are in late-stage development (versus 4), across 4 strategic therapeutic areas (versus 3).\n\nThe Company’s Alnylam P5x25 strategy is aimed at Alnylam’s transition to a top 5 biotech company, as measured by market capitalization, over the next 5 years.\n\nSpecifically, the Company intends to end 2025 with the following profile**:\n\n\nPatients: Over 0.5 million on Alnylam RNAi therapeutics globally\n\n\nProducts: 6 or more marketed products in rare and prevalent diseases\n\n\nPipeline: Over 20 clinical programs, with 10 or more in late stages and 4 or more INDs per year\n\n\nPerformance: ≥40% revenue CAGR through YE 2025\n\n\nProfitability: Achieve sustainable non-GAAP profitability within the period\n\n\n“We executed well on our Alnylam 2020 strategy, exceeding all pre-set metrics and transitioning into a glob...